Riluzole likely lacks antidepressant efficacy in ketamine non-responders.
作者信息
Niciu Mark J, Luckenbaugh David A, Ionescu Dawn F, Richards Erica M, Vande Voort Jennifer L, Ballard Elizabeth D, Brutsche Nancy E, Furey Maura L, Zarate Carlos A
机构信息
National Institutes of Health, National Institute of Mental Health, Experimental Therapeutics and Pathophysiology Branch (ETPB), 10 Center Dr., Building 10/CRC, Room 7-5545, Bethesda, MD 20892, USA.
National Institutes of Health, National Institute of Mental Health, Experimental Therapeutics and Pathophysiology Branch (ETPB), 10 Center Dr., Building 10/CRC, Room 7-5545, Bethesda, MD 20892, USA.
出版信息
J Psychiatr Res. 2014 Nov;58:197-9. doi: 10.1016/j.jpsychires.2014.07.022. Epub 2014 Aug 6.
Abstract
摘要
相似文献
1
Riluzole likely lacks antidepressant efficacy in ketamine non-responders.
J Psychiatr Res. 2014 Nov;58:197-9. doi: 10.1016/j.jpsychires.2014.07.022. Epub 2014 Aug 6.
2
Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Int J Neuropsychopharmacol. 2014 Oct 31;18(1):pyu039. doi: 10.1093/ijnp/pyu039.
3
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study.
Neuropsychopharmacology. 2012 May;37(6):1526-33. doi: 10.1038/npp.2011.338. Epub 2012 Feb 1.
4
Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression.
J Affect Disord. 2018 Dec 1;241:514-518. doi: 10.1016/j.jad.2018.08.075. Epub 2018 Aug 18.
5
Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.
Drugs Today (Barc). 2012 Jul;48(7):469-78. doi: 10.1358/dot.2012.48.7.1832873.
6
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Am J Psychiatry. 2013 Oct;170(10):1134-42. doi: 10.1176/appi.ajp.2013.13030392.
7
Ketamine for treatment-resistant depression: ready or not for clinical use?
Am J Psychiatry. 2013 Oct;170(10):1079-81. doi: 10.1176/appi.ajp.2013.13081034.
8
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.
Int J Neuropsychopharmacol. 2010 Feb;13(1):71-82. doi: 10.1017/S1461145709000169. Epub 2009 Mar 17.
9
Ketamine for Treatment-Resistant Depression: a New Advocate.
Rev Invest Clin. 2018;70(2):65-7. doi: 10.24875/RIC.18002501.
10
Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans.
Brain Behav. 2019 Nov;9(11):e01423. doi: 10.1002/brb3.1423. Epub 2019 Oct 15.
引用本文的文献
1
The Effect of Glutamatergic Modulators on Extracellular Glutamate: How Does this Information Contribute to the Discovery of Novel Antidepressants?
Curr Ther Res Clin Exp. 2019 Sep 10;91:25-32. doi: 10.1016/j.curtheres.2019.100566. eCollection 2019.
2
Glutamatergic Dysfunction and Glutamatergic Compounds for Major Psychiatric Disorders: Evidence From Clinical Neuroimaging Studies.
Front Psychiatry. 2019 Jan 24;9:767. doi: 10.3389/fpsyt.2018.00767. eCollection 2018.
3
The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder.
J Psychopharmacol. 2017 Dec;31(12):1570-1577. doi: 10.1177/0269881117732514. Epub 2017 Oct 17.
4
A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.
Neuropsychopharmacology. 2017 Dec;42(13):2567-2574. doi: 10.1038/npp.2017.106. Epub 2017 May 29.
5
Experimental medication treatment approaches for depression.
Transl Psychiatry. 2017 Mar 21;7(3):e1068. doi: 10.1038/tp.2017.33.
6
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.
Drugs. 2017 Mar;77(4):381-401. doi: 10.1007/s40265-017-0702-8.
7
Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders.
Neuropsychopharmacology. 2017 Jan;42(1):193-215. doi: 10.1038/npp.2016.199. Epub 2016 Sep 15.
8
An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder.
J Affect Disord. 2016 Apr;194:115-9. doi: 10.1016/j.jad.2016.01.009. Epub 2016 Jan 19.
9
Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder.
Mol Psychiatry. 2015 Oct;20(10):1142-50. doi: 10.1038/mp.2015.92. Epub 2015 Jul 7.
10
Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.
J Psychopharmacol. 2015 May;29(5):596-607. doi: 10.1177/0269881114568041. Epub 2015 Feb 17.
本文引用的文献
1
Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.
Annu Rev Pharmacol Toxicol. 2014;54:119-39. doi: 10.1146/annurev-pharmtox-011613-135950.
2
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study.
Neuropsychopharmacology. 2012 May;37(6):1526-33. doi: 10.1038/npp.2011.338. Epub 2012 Feb 1.
3
Overview of glutamatergic neurotransmission in the nervous system.
Pharmacol Biochem Behav. 2012 Feb;100(4):656-64. doi: 10.1016/j.pbb.2011.08.008. Epub 2011 Aug 26.
4
Therapeutic options for treatment-resistant depression.
CNS Drugs. 2010 Feb;24(2):131-61. doi: 10.2165/11530280-000000000-00000.
5
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.
Int J Neuropsychopharmacol. 2010 Feb;13(1):71-82. doi: 10.1017/S1461145709000169. Epub 2009 Mar 17.
6
Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole.
Mol Psychiatry. 2010 May;15(5):501-11. doi: 10.1038/mp.2008.106. Epub 2008 Sep 30.
7
Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.
Biol Psychiatry. 2007 Mar 15;61(6):822-5. doi: 10.1016/j.biopsych.2006.08.037. Epub 2006 Dec 4.
8
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression.
Biol Psychiatry. 2005 Feb 15;57(4):430-2. doi: 10.1016/j.biopsych.2004.11.023.
9
An open-label trial of riluzole in patients with treatment-resistant major depression.
Am J Psychiatry. 2004 Jan;161(1):171-4. doi: 10.1176/appi.ajp.161.1.171.
10
A new depression scale designed to be sensitive to change.
Br J Psychiatry. 1979 Apr;134:382-9. doi: 10.1192/bjp.134.4.382.
Zotero 插件